Effect of thymus-dependent antigen on recovery of hemo- and lymphopoiesis impaired by antineoplastic drugs

2000 ◽  
Vol 129 (6) ◽  
pp. 587-591
Author(s):  
N. V. Masnaya ◽  
G. M. Ratner
Keyword(s):  
Antineoplastic Drugs

Effects of cisplatin treatment on the rat neurohypophysis

1986 ◽  
Vol 44 ◽  
pp. 122-123
Author(s):  
J.M. Fadool ◽  
P.J. Boyer ◽  
S.K. Aggarwal
Keyword(s):  
Side Effects ◽  
Urine Output ◽  
Morphological Changes ◽  
Limiting Factor ◽  
Antineoplastic Drugs

Cisplatin (CDDP) is currently one of the most valuable antineoplastic drugs available. However, it has severe toxic side effects of which nephrotoxicity is the major dose limiting factor in its use. It induces morphological changes in the kidney with hampered urine output. The present study is an effort to determine the influence of the drug on the neurohypophysis for any antidiuretic effects on the kidney.

scholarly journals Characteristics of wipe sampling methods for antineoplastic drugs in North America: comparison of six providers

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Claire Chabut ◽  
Jean-François Bussières
Keyword(s):  
Environmental Monitoring ◽  
Service Provider ◽  
Sampling Methods ◽  
Service Providers ◽  
Limit Of Detection ◽  
The United States ◽  
Antineoplastic Drugs ◽  
Wipe Sampling ◽  
Pubmed Database ◽  
Google Search

Abstract Objectives Several societies have published guidelines to limit the occupational exposure of workers. Several of these guidelines recommend periodic (once or twice a year) environmental monitoring of specific sites where antineoplastic drugs are prepared and administered. However, most of the guidelines provide no guidance concerning which antineoplastic drugs should be monitored, the preferred sampling sites, appropriate test methods or limits of detection. The aim of this study was to characterize providers that quantify antineoplastic drug measured on surfaces. Methods This was a cross-sectional descriptive study. To identify service providers offering environmental monitoring tests, we searched the PubMed database and used the Google search engine. We contacted each service provider by email between June 3rd and June 15th, 2020. We specified the objective of our study and described the information needed and the variables of interest with standardized questions. Additional questions were sent by emails or via teleconferences. No statistical analyses were performed. Results We identified six providers offering services to Canadian hospitals, either based in Canada or in the United States. Five of these providers were private companies and one was a public organization. Each service provider was able to measure trace contamination of 3–17 antineoplastic drugs. Five of the providers quantified drugs using ultra performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MSMS), which allowed for lower LODs. The sixth provider offered quantification by immunoassay, which has higher LODs, but offers near real-time results; the surface area to be sampled with this method was also smaller than with UPLC-MSMS. The services offered varied among the service providers. The information about LODs supplied by each provider was often insufficient and the units were not standardized. A cost per drug quantified could not be obtained, because of variability in the scenarios involved (e.g. drug selection to be quantified, number of samples, nondisclosure of ancillary costs). Four of the six service providers were unable to report LOQ values. Conclusions Few data are available from Canadian service providers concerning the characteristics of wipe sampling methods for antineoplastics. This study identified six north-American providers. Their characteristics were very heterogeneous. Criteria to consider when choosing a provider include the validation of their analytical method, a low limit of detection, the choice of drugs to be quantified and the sites to be sampled, obtaining details about the method and understanding its limits, and price. This should be part of a structured multidisciplinary approach in each center.

Adsorption of Antineoplastic Drugs to Polyalkylcyanoacrylate Nanoparticles and Their Release in Calf Serum

1979 ◽  
Vol 68 (12) ◽  
pp. 1521-1524 ◽  
Author(s):  
P. Couvreur ◽  
B. Kante ◽  
M. Roland ◽  
P. Speiser
Keyword(s):  
Calf Serum ◽  
Antineoplastic Drugs

Neurotoxicity secondary to antineoplastic drugs

1994 ◽  
Vol 20 (2) ◽  
pp. 191-214 ◽  
Author(s):  
Malgorzata K. Tuxen ◽  
Steen Werner Hansen
Keyword(s):  
Antineoplastic Drugs

Antineoplastic drugs determination by HPLC-HRMSn to monitor occupational exposure

2015 ◽  
Vol 8 (7) ◽  
pp. 730-737 ◽  
Author(s):  
Federica Dal Bello ◽  
Valentina Santoro ◽  
Valentina Scarpino ◽  
Chiara Martano ◽  
Riccardo Aigotti ◽  
...  
Keyword(s):  
Occupational Exposure ◽  
Antineoplastic Drugs

Cardiotoxicity of copper-based antineoplastic drugs casiopeinas is related to inhibition of energy metabolism

2006 ◽  
Vol 212 (1) ◽  
pp. 79-88 ◽  
Author(s):  
Luz Hernández-Esquivel ◽  
Alvaro Marín-Hernández ◽  
Natalia Pavón ◽  
Karla Carvajal ◽  
Rafael Moreno-Sánchez
Keyword(s):  
Energy Metabolism ◽  
Antineoplastic Drugs

scholarly journals Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells

BMC Cancer ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
David J Taylor ◽  
Christine E Parsons ◽  
Haiyong Han ◽  
Arul Jayaraman ◽  
Kaushal Rege
Keyword(s):  
Cancer Cells ◽  
Antineoplastic Drugs ◽  
Parallel Screening ◽  
Induced Apoptosis ◽  
Apoptosis In Cancer Cells

Apoptosis May Be Either Suppressed or Enhanced with Strategic Combinations of Antineoplastic Drugs or Anti-IgM

1998 ◽  
Vol 244 (1) ◽  
pp. 1-13 ◽  
Author(s):  
Ching-Kow E. Lin ◽  
Tam Thuan Nguyen ◽  
Thomas L. Morgan ◽  
Rui-Lian Mei ◽  
John S. Kaptein ◽  
...  
Keyword(s):  
Antineoplastic Drugs
Sign in / Sign up

Export Citation Format

Share Document